BioNTech to pay €20M upfront, pick equity stake in Ryvu in license deal to boost cancer portfolio

Nov. 30, 2022 5:39 AM ETBioNTech SE (BNTX)By: Ravikash, SA News Editor7 Comments

Headquarters of the company Biontech in Mainz, Germany

U. J. Alexander

Germany's BioNTech (NASDAQ:BNTX) and Poland-based Ryvu Therapeutics signed a collaboration and license agreement for small molecule programs targeting immune modulation in cancer.

The global collaboration will consist of two parts: BioNTech will receive a global, exclusive license to develop

Recommended For You

Comments (7)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.